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Abstract
Aims/hypothesis Sugar-sweetened beverages (SSBs) are a
major dietary contributor to fructose intake. A molecular path-
way involving the carbohydrate responsive element-binding
protein (ChREBP) and the metabolic hormone fibroblast
growth factor 21 (FGF21) may influence sugar metabolism
and, thereby, contribute to fructose-inducedmetabolic disease.
We hypothesise that common variants in 11 genes involved in
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fructose metabolism and the ChREBP-FGF21 pathway may
interact with SSB intake to exacerbate positive associations
between higher SSB intake and glycaemic traits.
Methods Data from 11 cohorts (six discovery and five replica-
tion) in the CHARGE (Cohorts for Heart and Aging Research
in Genomic Epidemiology) Consortium provided association
and interaction results from 34,748 adults of European descent.
SSB intake (soft drinks, fruit punches, lemonades or other fruit
drinks) was derived from food-frequency questionnaires and
food diaries. In fixed-effects meta-analyses, we quantified: (1)
the associations between SSBs and glycaemic traits (fasting
glucose and fasting insulin); and (2) the interactions between
SSBs and 18 independent SNPs related to the ChREBP-
FGF21 pathway.
Results In our combined meta-analyses of discovery and rep-
lication cohorts, after adjustment for age, sex, energy intake,
BMI and other dietary covariates, each additional serving of
SSB intake was associated with higher fasting glucose
(β ± SE 0.014 ± 0.004 [mmol/l], p = 1.5 × 10−3) and higher
fasting insulin (0.030 ± 0.005 [loge pmol/l], p = 2.0 × 10
−10).
No significant interactions on glycaemic traits were observed
between SSB intake and selected SNPs. While a suggestive
interaction was observed in the discovery cohorts with a SNP
(rs1542423) in the β-Klotho (KLB) locus on fasting insulin
(0.030 ± 0.011 loge pmol/l, uncorrected p = 0.006), results in
the replication cohorts and combinedmeta-analyses were non-
significant.
Conclusions/interpretation In this largemeta-analysis, we ob-
served that SSB intake was associated with higher fasting
glucose and insulin. Although a suggestive interaction with
a genetic variant in the ChREBP-FGF21 pathway was ob-
served in the discovery cohorts, this observation was not con-
firmed in the replication analysis.
Trial registration Trials related to this study were registered at
clinicaltrials.gov as NCT00005131 (Atherosclerosis Risk in
Communities), NCT00005133 (Cardiovascular Health
Study), NCT00005121 (Framingham Offspring Study),
NCT00005487 (Multi-Ethnic Study of Atherosclerosis) and
NCT00005152 (Nurses’ Health Study).
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Introduction
Epidemiological evidence suggests that sugar-sweetened
beverage (SSB) intake is associated with increased risk
of the metabolic syndrome [1, 2] and type 2 diabetes [3].
Sucrose (table sugar) and high-fructose corn syrup are the
most common forms of sugar in SSBs, composed of near-
ly equal amounts of glucose and fructose [4]. Evidence
from some [5, 6], but not all [7, 8], human intervention
studies suggests that it is the fructose moiety which elicits
adverse cardiometabolic effects. Currently, an estimated
9.4% of adults in the USA have type 2 diabetes, while
34% have elevated blood glucose levels [9], a condition
associated with insulin resistance and increased risk for
type 2 diabetes. Excess sugar intake, particularly in the
form of SSBs, is one aspect of the diet that may impair
glucose homeostasis and contribute to greater insulin re-
sistance [3, 10, 11].
Carbohydrate responsive element-binding protein
(ChREBP, also known as MLX interacting protein like or
MLXIPL) is a transcription factor that responds to intracel-
lular carbohydrate metabolites and is a principal mediator
of carbohydrate-induced gene expression in key metabolic
tissues, including the liver [12–14]. Recent data indicate
that hepatic ChREBP is particularly responsive to fructose
intake [15] and contributes to fructose-induced lipid and
glycaemic abnormalities in animals and humans [16, 17].
Variants in the CHREBP (also known as MLXIPL) locus
associate with hypertriacylglycerolaemia and low HDL-
cholesterol at genome-wide significance levels [18, 19].
We have also demonstrated that fructose ingestion in
humans acutely increases circulating levels of the novel
metabolic hormone fibroblast growth factor 21 (FGF21),
and ChREBP is required for its activation [20, 21].
Pharmacological administration and genetic manipulation
of FGF21 has pleiotropic effects on carbohydrate and lipid
metabolism [22, 23]. We and others have recently reported
that SNPs in the FGF21 locus are associated with higher
circulating FGF21 concentrations and higher carbohydrate
relative to fat intake in humans [24, 25]. Together, these
data suggest that the ChREBP-FGF21 hormonal axis may
mediate an adaptive metabolic response to sugar
consumption.
Given a role for ChREBP in contributing to sugar-induced
derangements in both lipid and glucose homeostasis [26, 27],
we sought to test the hypothesis that variants associated with
hypertriacylglycerolaemia in the ChREBP pathway might in-
teract with SSB consumption to regulate glycaemic traits (see
the electronic supplementary material [ESM] for further de-
tails about SNP selection). Aside from variants in CHREBP,
we selected SNPs that have previously showed significant (i.e.
p < 5 × 10−8) or suggestive (i.e. p < 5 × 10−6) associations with
hypertriacylglycerolaemia or low HDL-cholesterol in human
genes important for hepatic fructose and glucose metabolism
(KHK, ALDOB, GCK, SLC2A2, SLC2A5) [17, 28–36]. We
also included other genes implicated in the regulation of both
ChREBP and blood triacylglycerol levels (FADS1 and TRIB1)
[37–41]. Finally, we included variants in the loci that code for
ChREBP-regulated metabolic hormone FGF21 and its obli-
gate receptor KLB [14, 20, 42, 43].
We hypothesised that common (minor allele frequency
[MAF] ≥5%) SNPs in these 11 genes may interact with SSB
intake to regulate glycaemic traits and, in particular, that risk
allele SNPs may exacerbate the positive associations between
SSB intake and glycaemic traits. The aims of the current in-
vestigation were to: 1) evaluate the relationship between SSB
intake and glycaemic traits, i.e. circulating levels of fasting
glucose and fasting insulin, in studies from the Cohorts for
Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium; and 2) examine whether these asso-
ciations are modified by SNPs related to ChREBP function.
Methods
Discovery and replication cohorts The present cross-
sectional meta-analyses included up to 34,748 participants of
European descent from 11 US and European cohort studies in
the CHARGE Consortium Nutrition Working Group (ESM
Table 1). Of those cohorts, six formed our discovery cohorts.
Five additional cohorts (replication cohorts) were later invited
to join the study to verify a suggestive interaction observed in
analyses of the discovery cohorts. Participants provided written
informed consent. The research protocol was approved by each
institutional review board and/or oversight committee.
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Dietary assessment, glycaemic trait measurements and
other relevant variables Dietary intake data were collected
by validated food-frequency questionnaires (FFQs) in all co-
horts, except in the Malmö Diet and Cancer [MDC] Study,
which estimated intake using FFQs in combination with a
7 day food record for prepared/cooked meals (ESM Table 2).
The type of FFQ used in each cohort differed slightly to cap-
ture the dietary habits of the specific population. SSB intake
included regular caffeinated, caffeine-free and carbonated
non-cola soft drinks (soda), and fruit-flavoured drinks, e.g.
lemonade, Hawaiian punch. Fruit juice (100%) was not in-
cluded in the estimation of SSBs with the exception of one
study (Western Australian Pregnancy Cohort Study [Raine])
that could not distinguish fruit juice from other beverages
based on their dietary assessment tool. One serving of SSB
was defined as 360 ml (12 fl oz.; the volume in one standard
soft drink can). Fruit intake, vegetable intake, whole grain
intake and fish intake in servings/day, alcohol intake in
grams/day and saturated fatty acid as percentage of total ener-
gy intake (where 1 g saturated fat has 37 kJ) were further
quantified and used as covariates in the present analysis.
SSB intake was considered continuously and further
dichotomised into low (<1 serving [<360 ml/day]) and high
(≥1 serving [≥360 ml/day]) intakes, whereas all remaining
dietary variables were considered continuously only.
Glycaemic biomarkers were typically measured after ≥8 h
fasting. Cohort-specific assessment methods for fasting glu-
cose and fasting insulin were quantified using similar proce-
dures, primarily by enzymaticmethods and radioimmunoassay,
respectively. Fasting glucose was not measured in one cohort
(Nurses’Health Study [NHS]). BMI was calculated frommea-
sured weight (kg) divided by height squared (m2). A descrip-
tion of cohort-specific methodologies for all relevant variables
is provided in ESM Table 3.
Genotyping Based on the hypothesis that genetic determinants
of fasting hypertriacylglycerolaemia and insulin insensitivity
may be shared, we used publicly available genotype-
phenotype data [44] to select SNPs that have previously
showed significant (i.e. p < 5 × 10−8) or suggestive (i.e.
p < 5 × 10−6) associations with hypertriacylglycerolaemia or
low HDL-cholesterol in humans, and were found within the
CHREBP gene or genes predicted to regulate either ChREBP
or the biological response to ChREBP activation. A total of 18
independent common (MAF ≥5%) SNPs in 11 genes in the
ChREBP-FGF21 pathwaywere included in the present analysis
(ESM Table 4).
In this analysis, SNPs were previously directly genotyped
or imputed by participating cohorts before inclusion (ESM
Table 5). SNPs were assessed for quality control using multi-
ple metrics (see ESMMethods [Genotype exclusion criteria]).
Not all SNPs were available in all participating cohorts (ESM
Table 6).
Cohort-specific analyses All discovery and replication co-
horts followed a uniform, pre-specified analysis plan.
Natural logarithmic transformation was applied to fasting in-
sulin. Participants within each cohort were excluded from the
present analysis when they had type 2 diabetes (prevalent or
self-reported), were taking medication for type 2 diabetes, had
fasting glucose ≥7 mmol/l (≥126 mg/dl) or were not fasting at
blood draw. Participants were also excluded if they had im-
plausible dietary data based on cohort-specific cut-points or
missing genotype data.
The main associations between SSB intake and fasting glu-
cose and insulin concentrations in the discovery and replication
cohorts were estimated using linear regression models or linear
mixed-effects models for family data, adjusted for the following
covariates: model 1 adjusted for age, sex, energy intake (kJ) and
study site for multi-centred cohorts (in the Cardiovascular
Health Study [CHS], Multi-Ethnic Study of Atherosclerosis
[MESA], Cardiovascular Risk in Young Finns Study [YFS]
and Atherosclerosis Risk In Communities [ARIC] Study);
model 2 adjusted for model 1 covariates plus smoking status,
education status, alcohol intake and physical activity (except
where unavailable: Rotterdam Study I [RS1], Rotterdam
Study II [RS2] and Raine); model 3 adjusted for model 2 co-
variates plus BMI; model 4 adjusted for model 3 covariates plus
fruit intake, vegetable intake, whole grain intake (except where
unavailable: Netherlands Epidemiology in Obesity Study
[NEO]), fish intake and saturated fatty acids (percentage of total
energy). As satiety responses and energy compensation differ
between men and women following SSB intake [45, 46], fur-
ther analyses were conducted using stratification by sex.
The main associations between selected SNPs and
glycaemic outcomes, as well as interaction analyses between
SSB intake and SNPs, were also investigated (see ESM
Methods [Genetic analyses]). In discovery cohorts, the inter-
action tests were performed for all selected SNPs on
glycaemic outcomes using linear regression analyses or linear
mixed-effects models for family data adjusted for age, sex,
energy intake, BMI, study site for multi-centred cohorts and
population structure where applicable. Suggestive interaction
results (i.e. p < 0.05) for one SNP from the discovery cohorts
was examined in the replication cohorts and further examined
in sex-specific analyses, and in analyses whereby SSB intake
was dichotomised into low (<1 serving/day) and high (≥1
serving/day) intakes. Secondary analyses examining sex-
stratified associations for all selected SNPs and interactions
were also pursued (see ESM Methods [Genetic analyses]).
Meta-analyses For the discovery cohorts, we conducted
inverse-variance weighted, fixed-effect meta-analyses using
the ‘metafor’ R package (https://cran.r-project.org) for the
main associations of SSB intake on fasting glucose and
insulin, selected SNPs on outcomes, interactions between
SSB intake and selected SNPs on outcomes, and sex-stratified
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main associations and interactions of the selected SNPs on out-
comes. Statistical significance for the association/interaction
tests was defined at a level of 0.001, based on Bonferroni cor-
rection for 36 (18 independent SNPs × 2 glycaemic outcomes)
total tests. We performed post hoc power calculations using
Quanto version 1.2.4 (http://biostats.usc.edu/Quanto.html)
(see ESM Methods [Power calculations]).
For suggestive interaction results (i.e. unadjusted p < 0.05)
from the discovery analyses, we further investigated: (1) the
main effect associations of SSB intake with fasting glucose
and insulin concentrations; (2) the main associations between
the nominally significant SNPs and glycaemic outcomes; and
(3) the interactions between SSB intake and nominally signifi-
cant SNPs on glycaemic outcomes in replication cohorts. These
suggestive interactions were further explored in sex-specific
meta-analyses and in meta-analyses with SSB intake
dichotomised into high and low intakes. In addition, we con-
ducted a combinedmeta-analysis (combined discovery and rep-
lication cohorts) for the described analyses.
Heterogeneity across studies was examined and, when de-
tected, followed by meta-regression and sensitivity analysis
described in the ESM Methods (Sensitivity analyses).
Finally, we ran random-effect meta-analyses for: (1) the main
associations of SSB intake on fasting glucose and insulin; and
(2) the interactions between SSB intake and selected SNPs on
outcomes for the combined meta-analyses.
Results
Study characteristics General demographic characteristics
and dietary intake of participants in the discovery and replica-
tion cohorts are provided in Table 1 (ESM Table 7 for sex-
stratified characteristics). The mean age ranged from 20.1 to
72.3 years and women comprised 52% to 100% within each
cohort. The mean SSB intake ranged from 0.10 servings/day
(RS1) to 0.98 servings/day (Raine). Mean BMI ranged from
24.5 to 29.6 kg/m2.
Associations of SSB intake with glycaemic traits
Associations between SSB intake and each glycaemic trait are
presented in Table 2 (Figs 1, 2). Results are presented for the
fully adjusted model (model 4), with other model results pre-
sented when findings varied. In the discovery cohort analyses,
we observed a positive association between SSB intake and
fasting insulin: each additional serving of SSB intake was as-
sociated with higher fasting insulin (β ± SE 0.027 ± 0.008 [loge
pmol/l], p = 1.4 × 10−3). No statistically significant associations
were observed between SSB intake and fasting glucose. In the
replication cohort analyses, we observed a positive association
between SSB intake and both fasting glucose (β ± SE
0.015 ± 0.005 (mmol/l), p = 2.3 × 10−3) and fasting insulin
(β ± SE 0.032 ± 0.006 [loge pmol/l], p = 3.3 × 10
−8). In
combined meta-analyses, associations for both fasting glucose
(β ± SE 0.014 ± 0.004 [mmol/l], p = 1.5 × 10−3) and fasting
insulin (β ± SE 0.030 ± 0.005 [loge pmol/l], p = 2.0 × 10
−10]
were also observed.
In sex-stratified analyses, we observed a positive associa-
tion between SSB intake and fasting glucose among women
only (men: β ± SE 0.001 ± 0.006 mmol/l, p = 0.82 [all co-
horts]; women: β ± SE 0.026 ± 0.006 mmol/l, p = 5.5 × 10−5
[all cohorts]), and between SSB intake and fasting insulin
among both men and women (men: β ± SE 0.029 ± 0.006
loge pmol/l, p = 4.5 × 10
−6; women:β ± SE 0.031 ± 0.007 loge
pmol/l, p = 1.7 × 10−5 [all cohorts]) (Table 3). Overall, low
heterogeneity (I2 < 30%) was observed in fasting glucose-
related analyses (model 4). Higher heterogeneity was ob-
served in fasting insulin analyses, particularly among replica-
tion cohorts (I2 69%).
Associations of SNPs with glycaemic traits The main asso-
ciations of selected SNPs on glycaemic traits are presented in
ESM Tables 8 and 9. In the meta-analysis, we replicated asso-
ciations between fasting glucose and GCK-rs4607517 [47],
GCKR-rs1260326 [48] and SLC2A2-rs11920090 [47] variants.
The association between fasting glucose andGCKR-rs1260326
was observed among women only (ESM Table 10). We also
replicated the association between fasting insulin and GCKR-
rs1260326 in the entire population and in sex-stratified analyses
(ESM Table 11) [48]. We found a novel, statistically significant
association between fasting glucose and FADS1-rs174546, and
observed nominally significant associations (p < 0.05) for
fasting glucose with KLB-rs1542423 and fasting glucose with
SLC2A2-rs11924032 (ESM Table 8).
Interactions between SSB intake and selected SNPs on
glycaemic traitsMeta-analysed estimates of the interactions
between SSB intake and selected SNPs on glycaemic traits
are presented in Table 4 (for sex-stratified results see ESM
Tables 12, 13). In the discovery cohort analyses, we did not
observe a statistically significant interaction between SSB
intake and any candidate SNP, even in sex-stratified inter-
action analyses. We did, however, observe a suggestive in-
teraction between SSB intake and KLB-rs1542423, an
intronic SNP in theβ-Klotho gene (KLB), for fasting insulin
(β ± SE 0.0302 ± 0.011 loge pmol/l, p = 0.006). The effect of
the interaction suggests a 0.0302 loge pmol/l higher fasting
insulin with each additional serving of SSB intake per copy
of the KLB-rs1542423 T allele (Fig. 3). This nominal inter-
action between SSB intake and KLB-rs1542423 for fasting
insulin was not supported in the replication cohort analyses
(β ± SE -0.0109 ± 0.0082 loge pmol/l, p = 0.18). The sug-
gestive interaction for this SNP was also lacking in com-
bined meta-analyses, sex-stratified analyses and analyses
with dichotomised SSB intake (Table 5, Fig. 3). See ESM
Results (Sex-stratified interaction analyses and Meta-
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regression and sensitivity analyses) for results of sex-
stratified analyses for additional SNPs (ESM Tables 13,
14), as well as results from meta-regression and sensitivity
analyses (ESM Tables 15, 16).
Discussion
In this meta-analysis involving more than 34,748 participants
free of type 2 diabetes in 11 cohort studies from the CHARGE
Table 2 Meta-analysis of main associations between SSB intake and glycaemic traits
Model Fasting glucose (mmol/l) Fasting insulin (loge pmol/l)
na β (SE) p I2 (%) na β (SE) p I2 (%)
Discovery cohorts
Model 1 16,739 0.009 (0.008) 0.27 34 16,304 0.032 (0.009) 5.3 × 10−4 39
Model 2 16,097 0.005 (0.009) 0.56 32 15,668 0.028 (0.009) 2.1 × 10−3 65
Model 3 16,024 0.010 (0.008) 0.20 0 15,594 0.036 (0.008) 8.8 × 10−6 35
Model 4 15,885 0.009 (0.008) 0.29 0 15,467 0.027 (0.008) 1.4 × 10−3 13
Replication cohorts
Model 1 18,719 0.020 (0.005) 2.9 × 10−5 0 19,265 0.056 (0.006) <1.0 × 10−10 45
Model 2 18,527 0.019 (0.005) 8.6 × 10−5 0 19,075 0.045 (0.006) <1.0 × 10−10 53
Model 3 18,508 0.015 (0.005) 1.4 × 10−3 0 19,059 0.036 (0.005) <1.0 × 10−10 63
Model 4 18,505 0.015 (0.005) 2.3 × 10−3 0 19,056 0.032 (0.006) 3.3 × 10−8 69
All cohorts
Model 1 35,458 0.017 (0.004) 2.9 × 10−5 15 35,569 0.049 (0.005) <1.0 × 10−10 51
Model 2 34,624 0.016 (0.004) 2.1 × 10−4 14 34,743 0.040 (0.005) <1.0 × 10−10 60
Model 3 34,532 0.014 (0.004) 6.6 × 10−4 0 34,653 0.036 (0.004) <1.0 × 10−10 46
Model 4 34,390 0.014 (0.004) 1.5 × 10−3 0 34,523 0.030 (0.005) 2.0 × 10−10 48
Regression coefficients are shown as β (SE). β represents the change in outcome per additional serving/day of SSB
Model 1: adjusted for age, sex, total energy intake and study site for multi-centred cohorts (in CHS, MESA, YFS)
Model 2: adjusted for model 1 covariates and smoking status, education status, physical activity (except in RS1, RS2) and alcohol intake
Model 3: adjusted for model 2 covariates and BMI
Model 4: adjusted for model 3 covariates and fruit intake, vegetable intake, whole grain intake, fish intake and saturated fatty acids (% total energy)
a Number of independent observations in each association analysis
β (95% CI)Discovery cohorts
CHS 0.04 (-0.04, 0.12)
FHS 0.01 (-0.01, 0.03)
MESA 0.01 (-0.04, 0.06)
RS1 0.15 (-0.01, 0.31)
RS2 -0.03 (-0.22, 0.16)
YFS 0 (-0.05, 0.05)
Discovery meta-analysis 0.01 (-0.01, 0.03)
Replication cohorts
ARIC 0.02 (0.01, 0.04)
MDC 0.02 (-0.01, 0.05)
NEO 0.01 (-0.01, 0.03)
Raine 0.01 (-0.01, 0.04)
Replication meta-analysis 0.02 (0.01, 0.02)
All cohorts meta-analysis 0.01 (0.01, 0.02)
Mean difference in FG (mmol/l) per each additional serving/day of SSB intake
−0.3 −0.1 0 0.1 0.3
Fig. 1 Forest plot of main
association between SSB intake
and fasting glucose (FG)
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Consortium, we observed significant associations between SSB
intake and fasting glucose and insulin concentrations, indepen-
dent of demographics, overall adiposity, total energy intake and
other dietary factors. We adjusted for BMI to consider whether
obesity may be in the causal pathway between SSB and fasting
insulin or glucose, since consuming SSB may lead to a higher
BMI, and a higher BMI is associated with worsening glycaemic
traits. We observed that the results remained largely the same
without attenuation after accounting for BMI, suggesting that
although SSBs may increase body weight and adiposity, the
relationship with glycaemic traits is independent from adiposi-
ty. For each additional serving of SSBs, fasting insulin was 3%
higher. The SSB association with fasting glucose was less con-
sistent. Significant associations were observed only in the rep-
lication cohorts, and in the meta-analysis of all cohorts only in
women. There was no evidence of SNP–SSB interactions in the
meta-analysis of all cohorts or in the sex-stratified analysis.
This is the first meta-analysis to assess the association of
SSB intake with measures of diabetic risk factors and con-
firms the positive association between SSB consumption and
insulin resistance (HOMA-IR or fasting insulin) suggested by
cross-sectional studies in adults [10, 11], young children [49]
and adolescents [50, 51]. However, in well-controlled, short-
term intervention studies in healthy adults, the evidence is less
consistent with some studies reporting that consumption of
fructose-containing sugars for 3–10 weeks has a detrimental
effect on insulin sensitivity [5, 6, 52], whereas others observed
no significant detrimental effect on insulin resistance [53, 54].
Nevertheless, given the observed associations between SSB
intake and risk of diabetes [2, 3, 55], our results further favour
efforts to assess the potential beneficial effects of reducing
SSB consumption on cardiometabolic risk factors in human
populations.
In this meta-analysis, we confirmed the previously reported
SNP associations with fasting glucose and insulin in GCK-
rs4607517 [47], GCKR-rs1260326 [48], SLC2A2-
rs11920090 [47] and GCKR-rs1260326 in women only [48].
We also observed a positive association between fasting glu-
cose and the FADS1-rs174546 variant, which is in linkage
disequilibrium with FADS1-rs174550, recognised as having
an association with fasting glucose [47] and also in linkage
disequilibrium with the FADS1-rs174547 variant, which has
been associatedwith atherogenic dyslipidaemia.While we have
not formally investigated the relationship between SSB intake
and our selected SNPs, our lookup in a large macronutrient
intake genome-wide association study from the CHARGE
Consortium indicates an association between the FGF21-
rs8381.33 variant and carbohydrate intake (ESM Table 17).
To date, few studies have considered whether genetic varia-
tion impacts the susceptibility to the detrimental effects of SSB
intake on key cardiometabolic traits. In a large cohort of men
and women in the USA [56], as well as two large Swedish [57]
and Finnish cohorts [58], SSB intake significantly interacted
with underlying genetic predisposition for weight gain and obe-
sity risk. More recently, daily SSB intake was observed to in-
teract with variants in the 9p21 region to exacerbate the genetic
predisposition effects on coronary artery disease in Hispanics
living in Costa Rica [59]. In Hispanic children, the effects of
PNPLA3 on liver fat were exacerbated under conditions of a
high carbohydrate diet, in particular high sugar intake [60].
Although limited to a few studies, the findings indicate that
SSB intake may interact with genetic variants to increase car-
diometabolic risk in susceptible individuals.
Here, we pursued a candidate approach to examine whether
SNPs in a ChREBP-FGF21 pathway might interact with SSB
intake to regulate glycaemic traits. In the discovery phase of
β (95% CI)Discovery cohorts
CHS 0.09 (0.03, 0.15)
FHS 0.02 (0, 0.04)
MESA 0.03 (-0.03, 0.08)
RS1 0.06 (-0.02, 0.14)
RS2 0.03 (-0.06, 0.13)
YFS 0 (-0.08, 0.09)
0.03 (0.01, 0.05)Discovery meta-analysis
Replication cohorts
ARIC 0.04 (0.02, 0.06)
MDC 0.06 (0.03, 0.08)
NEO 0.02 (0, 0.04)
NHS 0.09 (-0.03, 0.22)
Raine -0.02 (-0.06, 0.02)
0.03 (0.01, 0.05)Replication meta-analysis
All cohorts meta-analysis 0.03 (0.02, 0.04)
Multiplicative difference in FI (log
e
 pmol/l) per each additional serving/day of SSB intake
−0.3 −0.1 0 0.1 0.3
Fig. 2 Forest plot of main
association between SSB intake
and fasting insulin (FI)
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our analysis, we identified a promising interaction between
the KLB SNP (rs1542423) and SSB for fasting insulin. We
observed that individuals who carried a T allele in this SNP
consistently had a higher level of fasting insulin in response to
high SSB intake in five of the six discovery cohorts. Because
these data were consistent with our hypothesis that variants in
a ChREBP-FGF21 signalling axis might regulate metabolic
traits in response to SSB intake, we sought out replication
cohorts to further test this suggestive interaction. The interac-
tion between SSB intake and KLB-rs1542423 for fasting in-
sulin was not significant in the replication cohorts, or in the
combined meta-analysis of all 11 participating cohorts, sug-
gesting a false-positive finding. Because we observed a sex-
specific main association between SSB intake and fasting glu-
cose, we pursued sex-stratified interaction analyses of SSB
intake by selected SNPs as a secondary analysis. We observed
Table 3 Meta-analysis of main associations between SSB intake and glycaemic traits stratified by sex in all participating cohorts
Model Fasting glucose (mmol/l) Fasting insulin (loge pmol/l)
na β (SE) p I2 (%) na β (SE) p I2 (%)
Men
Discovery cohorts
Model 1 6919 0.001 (0.011) 0.89 0 6636 0.028 (0.012) 0.02 27
Model 2 6638 −0.0004 (0.011) 0.97 0 6356 0.026 (0.012) 0.03 4
Model 3 6613 0.003 (0.011) 0.78 0 6331 0.033 (0.010) 1.4 × 10−3 0
Model 4 6554 −0.001 (0.011) 0.91 0 6276 0.032 (0.008) 0.03 0
Replication cohorts
Model 1 8942 0.005 (0.007) 0.41 0 8484 0.054 (0.008) <1.0 × 10−10 66
Model 2 8454 0.009 (0.007) 0.19 0 8397 0.047 (0.008) 7.7 × 10−9 70
Model 3 8447 0.004 (0.006) 0.52 0 8392 0.033 (0.007) 5.6 × 10−6 67
Model 4 8446 0.002 (0.007) 0.74 0 8391 0.030 (0.018) 4.6 × 10−5 77
All cohorts
Model 1 15,861 0.004 (0.006) 0.44 0 15,120 0.045 (0.007) <1.0 × 10−10 52
Model 2 15,092 0.006 (0.006) 0.28 0 14,753 0.041 (0.007) 2.0 × 10−9 48
Model 3 15,060 0.004 (0.006) 0.48 0 14,723 0.033 (0.006) 2.9 × 10−8 35
Model 4 15,000 0.001 (0.006) 0.82 0 14,667 0.029 (0.006) 4.5 × 10−6 48
Women
Discovery cohorts
Model 1 9181 0.032 (0.014) 0.02 70 8811 0.061 (0.014) 2.0 × 10−5 43
Model 2 8822 0.020 (0.014) 0.15 70 8457 0.043 (0.015) 3.4 × 10−3 53
Model 3 8774 0.028 (0.013) 0.03 55 8408 0.051 (0.013) 5.6 × 10−5 0
Model 4 8694 0.032 (0.014) 0.02 59 8336 0.041 (0.013) 1.6 × 10−3 0
Replication cohorts
Model 1 10,177 0.032 (0.007) 1.0 × 10−6 0 10,781 0.059 (0.009) 1.9 × 10−11 0
Model 2 10,073 0.027 (0.007) 1.2 × 10−4 0 10,678 0.042 (0.009) 2.3 × 10−6 0
Model 3 10,061 0.021 (0.007) 1.7 × 10−3 0 10,667 0.037 (0.008) 1.8 × 10−6 14
Model 4 10,059 0.024 (0.007) 9.1 × 10−4 0 10,665 0.027 (0.009) 2.1 × 10−3 5
All cohorts
Model 1 19,358 0.032 (0.006) 6.1 × 10−8 49 19,592 0.059 (0.007) 1.9 × 10−15 6
Model 2 18,895 0.026 (0.006) 4.2 × 10−5 49 19,135 0.042 (0.008) 2.7 × 10−8 20
Model 3 18,835 0.022 (0.006) 1.6 × 10−4 31 19,075 0.041 (0.007) 6.0 × 10−10 0
Model 4 18,753 0.026 (0.006) 5.5 × 10−5 39 19,001 0.031 (0.007) 1.7 × 10−5 0
Regression coefficients are shown as β (SE). β represents the change in outcome per additional serving/day of SSB
Model 1: adjusted for age, total energy intake and study site for multi-centred cohorts (in CHS, MESA, YFS)
Model 2: adjusted for Model 1 covariates and smoking status, education status, physical activity (except in RS1, RS2) and alcohol intake
Model 3: adjusted for Model 2 covariates and BMI
Model 4: adjusted for Model 3 covariates and fruit intake, vegetable intake, whole grain intake, fish intake and saturated fatty acids (% total energy)
a Number of independent observations in each association analysis
Diabetologia (2018) 61:317–330 325
a suggestive interaction between SSB intake with one SNP in
men (FGF21-rs838133) and one SNP (GCK-rs4607517) in
women for fasting insulin.
There are several limitations to our study. One limitation is
the focus on a small number of SNPs in a hypothesised candi-
date gene pathway. While this excludes many other genes and
regulatory regions, the focus provides a testable hypothesis and
reduces the penalty for genome-wide testing. Sufficiently large
populations with the requisite genotyping, phenotyping and di-
etary information do not yet exist to achieve statistical power
sufficient for a genome-wide approach. A second limitation is
the heterogeneity within the discovery cohorts as well as
heterogeneity between the discovery and replication cohorts.
Although cohort inclusion is based upon European ancestry,
each cohort has unique characteristics in terms of location,
age, sex and covariate structure. For example, participants were,
on average, younger in the replication cohorts compared with
the discovery cohorts (mean age 54.2 vs 57.6 years). We have
also observed additional significant differences in fasting insu-
lin and SSB intake, among other general characteristics includ-
ing BMI, smoking, education and energy intake (ESM
Table 18). Although we attempted to adjust for age in our
regression models, this difference in age could have a non-
linear impact on the effects of the variant on SSB-induced in-
sulin resistance, thereby contributing to residual confounding.
The difference in age could contribute to the difference in SSB
intake as the mean SSB intake was higher in the replication
cohorts (0.19 to 0.98 servings/day) compared with the discov-
ery cohorts (0.10 to 0.32 servings/day) (p < 0.0001).
Furthermore, meta-regression findings suggest differences in
the magnitude, but not significance, of the associations between
SSB intake and fasting insulin. This may be a result of differ-
ences in the moderator in the analysis, such as age and BMI, or
as a result of other trait differences in the cohorts. Despite those
differences, the associations still remain in subgroup analyses,
with the exception of subgroup analyses by sample size, possi-
bly as a result of low power in the analyses with smaller cohorts.
It is important to note that these analyses use a cross-
sectional design, incorporating the phenotypic measures
(fasting glucose and fasting insulin) and SSB intake at one
point in time. Although many of the cohorts contributing to
the analyses are longitudinal in nature, not all have measures
of outcome and exposure longitudinally. Thus, we did not
capture long-term SSB intake patterns, which probably
Table 4 Meta-analysis of interactions between SSB intake and SNPs on glycaemic traits in discovery cohorts
SNP Chromosome Gene Allelesa Fasting glucose (mmol/l) Fasting insulin (loge pmol/l)
β (SE) p β (SE) p
rs10819937 9 ALDOB C/G −0.0067 (0.0147) 0.65 −0.0059 (0.0148) 0.69
rs10819931 9 ALDOB T/C −0.0229 (0.0215) 0.29 0.0023 (0.0212) 0.92
rs174546 11 FADS1 T/C 0.0018 (0.0116) 0.87 0.0070 (0.0115) 0.54
rs838133 19 FGF21 A/G −0.0149 (0.0128) 0.24 −0.0176 (0.013) 0.17
rs4607517 7 GCK A/G −0.0020 (0.0145) 0.89 0.0101 (0.0144) 0.48
rs1260326 2 GCKR C/T −0.0015 (0.0105) 0.89 −0.0088 (0.0104) 0.40
rs2119026 2 KHK C/T −0.0111 (0.0119) 0.35 0.0059 (0.0119) 0.62
rs1542423 4 KLB T/C −0.0105 (0.0111) 0.34 0.0302 (0.0110) 0.006**
rs799166 7 CHREBP/MLXIPL C/G −0.0084 (0.0175) 0.63 0.0183 (0.0187) 0.33
rs799168 7 CHREBP/MLXIPL G/A −0.0229 (0.0164) 0.16 0.0173 (0.0176) 0.33
rs799160 7 CHREBP/MLXIPL T/C −0.0149 (0.0159) 0.35 0.0091 (0.0165) 0.58
rs11974409 7 TBL2 A/G −0.0095 (0.0139) 0.50 0.0086 (0.0144) 0.55
rs11920090 3 SLC2A2 A/T 0.0214 (0.0165) 0.19 0.0123 (0.0165) 0.46
rs11924032 3 SLC2A2 A/G 0.0142 (0.0117) 0.23 −0.0023 (0.0117) 0.84
rs5438 1 SLC2A5 A/G 0.0220 (0.0283) 0.78 −0.011 (0.0283) 0.70
rs3820034 1 SLC2A5 C/T 0.0140 (0.0140) 0.32 0.0009 (0.0142) 0.95
rs5840 1 SLC2A5 T/C 0.0109 (0.0112) 0.33 0.0002 (0.0112) 0.98
rs2954029 8 TRIB1 A/T 0.0186 (0.0111) 0.09 0.0069 (0.0112) 0.54
Interaction coefficients are shown asβ (SE).β represents the direction andmagnitude of the change in outcome trait with each additional effect allele, per
each additional serving/day of SSB intake
Additive allele mode adjusted for age, sex, BMI, study site for multi-centred cohorts (in CHS, MESA, YFS), and family or population structure where
applicable (in FHS, MESA, RS1, RS2, YFS)
a Alleles presented as effect/non-effect alleles
**p < 0.01
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change with age, and thus misclassification of dietary expo-
sure may vary across cohorts. Furthermore, SSB intake was
significantly associated with fasting glucose among women,
but not men. It has been noted that the effects of excessive
sugars on glycaemic traits in animal models are sexually di-
morphic although the pattern is not the same as observed here
[61]. Though we have no mechanistic explanation for the
difference at this time, our results support the need for future
studies concerning the metabolic effects of SSBs to carefully
consider sex-based stratification.
Finally, the use of self-reported data in our assessment of
dietary intake may be susceptible to reporting bias, such as
under-reporting, and the validity of questionnaires may vary
across cohorts, thereby potentially attenuating associations.
Strengths of the study include the large sample size attained
by our meta-analytic approach necessary to detect gene–envi-
ronment interactions. Our collaborative approach also en-
abled us to standardise our analyses across cohorts. The ob-
served interaction regression coefficients were small compared
with the magnitude of interaction observed in other studies
looking at gene–environment interactions between SSBs and
cardiometabolic outcomes [56, 59]. Thus, even with the large
sample size in this study, it is possible that we were insufficient-
ly powered to detect and replicate a small gene–SSB interac-
tion. If such interactions did exist, but are too small to be de-
tected in this analysis, the clinical relevance of such small in-
teractions might be questioned. Nevertheless, our candidate
gene approach was suggestive of interaction at one locus, and
the ChREBP-FGF21 pathway remains mechanistically
interesting.
Table 5 Meta-analysis of interactions between SSB intake and rs1542423 on fasting insulin
Discovery cohorts Replication cohorts All cohorts
n β (SE) p I2
(%)
n β (SE) p I2
(%)
n β (SE) p I2
(%)
All 15,590 0.0302 (0.011) 0.006** 0 18,338 −0.0109 (0.0082) 0.18 21 33,928 0.0037 (0.0066) 0.57 46
Men 6379 0.0230 (0.0140) 0.10 0 8083 −0.0121 (0.0108) 0.26 0 14,462 0.0009 (0.0086) 0.91 7
Women 8366 0.0308 (0.0180) 0.09 0 10,357 −0.0178 (0.0124) 0.15 0 18,723 −0.0021 (0.0102) 0.83 23
Dichotomised
SSB intake
12,001 0.0340 (0.0302) 0.26 0 18,430 −0.0155 (0.0198) 0.43 0 30,431 −0.0006 (0.0166) 0.97 0
Interaction coefficients are shown asβ (SE).β represents the direction andmagnitude of the change in outcome trait with each additional effect allele, per
each additional serving/day of SSB intake
Additive allele mode adjusted for age, sex, BMI, study site for multi-centred cohorts (in CHS, MESA, YFS), and family or population structure where
applicable (in FHS, MESA, RS1, RS2, YFS)
**p < 0.01
β (95% CI)Discovery cohorts
-0.01 (-0.13, 0.12)CHS





0.03 (0.01, 0.05)Discovery meta-analysis
Replication cohorts 
ARIC 0 (-0.02, 0.03)
-0.01 (-0.06, 0.04)MDC
NEO -0.03 (-0.06, 0)
0.02 (-0.16, 0.21)NHS
-0.05 (0.13, 0.03)Raine
Replication meta-analysis -0.01 (-0.03, 0.01)
All cohorts meta-analysis 0 (-0.01, 0.02)
Multiplicative difference in FI (log
e
 pmol/l) with each additional effect allele,
per each additional serving/day of SSB intake
−0.3 −0.1 0 0.1 0.3
Fig. 3 Forest plot of interaction
between SSB intake and
rs1542423 on fasting insulin (FI)
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Variants within the CHREBP locus associate with
hypertriacylglycerolaemia [18, 19]. For this analysis, SNPs with-
in candidate genes in a putative ChREBP-FGF21 signalling axis
(ESM Table 4) were selected based on genome-wide or sub-
genome-wide association with fasting triacylglycerol levels,
and not on the basis of glycaemic traits. This approach was
pursued because excess sugar consumption is thought to cause
hypertriacylglycerolaemia, and hypertriacylglycerolaemia and
insulin resistance are linked epidemiologically and may share
common pathogenic mechanisms [26, 62, 63]. Thus, implicit to
this strategy is the hypothesis that genetic determinants of fasting
hypertriacylglycerolaemia may be linked to insulin sensitivity.
One limitation of this approach is that mechanisms mediating
sugar-induced hypertriacylglycerolaemia and insulin resistance
may be distinct. A second limitation is that our analyses were
limited to 18 lead SNPs, and it is possible that SNPs that interact
with the environment to associate with a trait are distinct from the
variants that associate with a trait unconditioned on the environ-
ment, particularly those associating with a trait at genome-wide
significance threshold. Thus, it may be necessary to examine all
SNPs within a locus of interest as opposed to a lead SNP, al-
though this would further increase the burden of multiple testing.
Future studies should undertake a more comprehensive testing
for interactions between SSB intake and key genes like KLB on
glycaemic outcomes.
In summary, the present observational study from 11 co-
horts is the largest investigation of the relationship between
SSB intake, genetics and glycaemic traits. We observed that
SSB intake was positively associated with higher fasting in-
sulin and glucose. Although a suggestive interaction with a
genetic variant in the ChREBP-FGF21 signalling axis was
observed in the discovery cohorts, this observation was not
confirmed in the replication analysis. In conclusion, our re-
sults suggest that SSB consumption may unfavourably impact
glucose homeostasis in different populations, regardless of
genotypes at loci within the ChREBP-FGF21 signalling axis.
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